# National Cancer Center, Japan: Phase 2 study in Ovarian Clear Cell Carcinoma (32 participants)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | National Cancer Center, Japan |
| Sponsor type | Non-US government |
| Study | A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy（NCCH2407/MK014） |
| NCT ID | NCT07913568 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Ovarian Clear Cell Carcinoma |
| Intervention types | drug |
| Target enrollment | 32 |
| Site countries | Japan |
| Posted | 2026-11-03 |
| Planned start | 2027-02-01 |
| Event | Newly registered study |
| Event date | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07913568). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.